EPISODE · Dec 6, 2023 · 28 MIN
Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
from Keeping Current CME
Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu
Embed this episode
NOW PLAYING
Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
0:00
28:47
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 28 minutes long.
When was this Keeping Current CME episode published?
This episode was published on December 6, 2023.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!